Research programme: cyclin-dependent kinase 8/19 inhibitors - Senex Biotechnology

Drug Profile

Research programme: cyclin-dependent kinase 8/19 inhibitors - Senex Biotechnology

Alternative Names: Senexin B

Latest Information Update: 28 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Senex Biotechnology
  • Class Proteins; Small molecules
  • Mechanism of Action Cyclin dependent kinase 19 inhibitors; Cyclin-dependent kinase 8 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Prostate cancer
  • Research Cardiovascular disorders; Inflammation; Viral infections

Most Recent Events

  • 28 Nov 2017 Early research in Cardiovascular disorders in USA, prior to November 2017 (Senex Biotechnology pipeline, November 2017)
  • 28 Nov 2017 Early research in Inflammation in USA, prior to November 2017 (Senex Biotechnology pipeline, November 2017)
  • 28 Nov 2017 Early research in Viral infections in USA, prior to November 2017 (Senex Biotechnology pipeline, November 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top